|
| Reference | Location, year | Clonal type | Antimicrobial susceptibility | Mechanism of antimicrobial resistance | Notes |
|
| Figueiredo-Mendes et al. 2005 [29] | São Paulo, Brazil (4 centers) and Brasília, Brazil (1 center), 2002 | 36 P. aeruginosa isolates (clones A, B, C, D, and G) | Multidrug resistant; carbapenem MIC, ≥32 µg/mL | MBL production (except for clone D1 and D2) | Interhospital spread probably owing to transfers of infected patients, share of health care workers, and exchange of medical equipment among institutions |
|
| Gales et al. 2004 [30] | Hospital Universitário São Francisco, São Paulo, Brazil, 2001 | 5 carbapenem-resistant P. aeruginosa strains from 4 patients (clone B and C1) | Clone B susceptible to all classes except carbapenems; clone C1 susceptible to polymyxin B only | NR | Dissemination may have been owing to cross-contamination. Clone C1 had a similar PGFE pattern to clone C2 (previously isolated from Hospital São Paulo, São Paulo, Brazil) |
|
| Cezário et al. 2009 [31] | University Hospital in Minas Gerais, Brazil, 2003–2005 | 36 multidrug P. aeruginosa isolates (clones A, B, C, and D) | Multidrug resistant | MBL-producing strains were positive for blaSPM-1 | Strong temporal/spatial relationship indicated cross-contamination |
|
| Córdova et al. 2012 [32] | Hospital Dr. Cosme Argerich, Buenos Aires, Argentina, 2009-2010 | 6 patients infected with KPC-producing K. pneumoniae ST258 | Susceptible to tigecycline and colistin only | KPC | Attributable mortality, 26%; ST258 had a high capacity for dissemination |
|
